FDA Probes Risks of HIV, Prostate, Other Drugs

FDA Probes Risks of HIV, Prostate, Other Drugs
Abstract
The Food and Drug Administration’s latest Adverse Event Reporting System update indicates the agency is investigating potential safety issues associated with the HIV drug Kaletra and several other medications. FDA said it is tracking reports of liver toxicity in patients who received Kaletra to prevent HIV infection following exposure to the virus (post-exposure prophylaxis). FDA also is looking into reports of male breast cancer in patients taking the prostate drugs Avodart or Proscar, and in those taking the baldness product Propecia. The quarterly report covers the period October through December 2009. FDA emphasized that “the listing of a drug and a potential safety issue on this Web site does not mean that FDA is suggesting prescribers should not prescribe the drug or that patients taking the drug should stop taking the medication.” For more information, visit http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm210293.htm


Source
http://www.reuters.com

Date of Publication
05/03/2010

Author
Lisa Richwine

Article Type
General media

Article Category
News Briefs

Subjects
Adverse Reactions
HIV/AIDS Treatment or Therapies


----------------------------
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, news, funding opportunities, organizations, and conferences do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.


cdcnpin.org News Record #55254